by Stacey Johnson | Mar 11, 2016
Tissue engineering is a key part of regenerative medicine (RM), but it sometimes feels like the poor cousin of stem cells. The Jan to big sister Marcia. That won’t be the case at the upcoming 10th World Biomaterials Congress (WBC2016), happening May 17-22 in Montreal,...
by James Smith | Mar 7, 2016
Post by James Smith and Mackenna Roberts. Ms. Roberts is an English-qualified lawyer, trained bioethicist and strategic adviser for the commercialization of emerging biomedical technologies and is widely published on how the law should govern cutting-edge medical...
by Nicole Kuchinsky | Feb 29, 2016
Japan is making bold moves to redefine how cell therapies make it to market, and the world is taking notice. In late January, the Japan External Trade Organization (JETRO) collaborated with the Centre for Commercialization of Regenerative Medicine (CCRM) to host a...
by Mark Curtis | Feb 18, 2016
Welcome to your Cell Therapy Deal Review for the month of January. Things got off to a quick start with a number of cell-based immunotherapy companies announcing deals and research collaborations out of the gate, including a third acquisition by Juno. Juno...
by Nicole Kuchinsky | Feb 17, 2016
Cell therapy is not a new idea. Bone marrow transplantation—the first ever cell therapy—has been around since the 1950s. Over half a century of research has brought important advancements, yet this technology has struggled to make it to prime time. Understandably,...
Comments